GSK and SpringWorks to end Blenrep combination collab

11 June 2024
springworks_large

UK pharma major GSK (LSE: GSK) and US biotech SpringWorks Therapeutics (Nasdaq: SWTX) are to end their collaboration combining Blenrep (belantamab mafodotin) and Ogsiveo (nirogacestat).

The companies were hoping that GSK’s BCMA-targeting antibody-drug conjugate Blenrep and SpringWorks’ oral gamma secretase inhibitor Ogsiveo would work in multiple myeloma, and agreed to combine them in a global, non-exclusive license and collaboration agreement.

GSK and SpringWorks first started working together on the pairing in 2019 - later amending this collaboration in 2021 - in patients with relapsed or refractory multiple myeloma. The expanded agreement that was signed in 2022 allowed for studying the combination in earlier lines of treatment, including newly-diagnosed patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology